CD38 and nervous system disorder: In treatment-refractory antibody-mediated neurological disorders, daratumumab treatment has been associated with reductions in CD38-expressing T cells, NK cells, and serum neurofilament light chain levels, suggesting immunomodulatory effects and attenuation of active axonal injury (9).